Ouyang Guoqing, Pan Guangdong, Wu Yongrong, Liu Qiang, Lu Wuchang, Chen Xiang
Department of Hepatobiliary Surgery, Liuzhou People's Hospital, Liuzhou, Guangxi, People's Republic of China.
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Cancer Manag Res. 2020 Sep 21;12:8721-8732. doi: 10.2147/CMAR.S263370. eCollection 2020.
Gamma-glutamyltransferase (GGT) and alkaline phosphatase (ALP) were involved in the development and progression of cancers. This study aimed to evaluate the prognostic value of a preoperative GGT:ALP ratio (GAR) in hepatocellular carcinoma (HCC) patients with curative liver resection.
A total of 380 HCC patients underwent curative liver resection before December 2017 and from January to December 2018 were included and stratified into training set and validation set, respectively. Prediction accuracy was evaluated by the area under the receiver operating characteristic curve (AUC). Factors determined to be significant for overall survival (OS) and tumor-free survival (TFS) by using Cox regression analysis. The Kaplan-Meier method and Log rank test were utilized for survival analysis.
The AUC of GAR was 0.70 (P < 0.001). An optimal cut-off value of 0.91 yielded a sensitivity of 78.1% and a specificity of 60.4% for GAR ( < 0.001), which stratified the HCC patients into high-risk (>0.91) and low-risk (≤ 0.91) groups. Time-dependent ROC revealed that the AUCs for 1-, 3-, and 5-year OS predictions for GAR were 0.60, 0.69 and 0.62, respectively. In addition, GAR was identified as an independent risk factor for OS and TFS both in training and validation cohort by univariate and multivariate Cox regression analysis, as well as a good prognostic indicator for patients with Barcelona Clinic Liver Cancer stage C or without vascular invasion. Notably, the AUC of the GAR for survival was better than several potential prognostic indices ( < 0.05).
We identified the GAR as a prognostic indicator in two independent cohorts of HCC patients with curative liver resection. The patients with decreased GAR score were significantly associated with better OS and TFS.
γ-谷氨酰转移酶(GGT)和碱性磷酸酶(ALP)参与癌症的发生和发展。本研究旨在评估术前GGT:ALP比值(GAR)对接受根治性肝切除术的肝细胞癌(HCC)患者的预后价值。
纳入2017年12月前以及2018年1月至12月期间共380例行根治性肝切除术的HCC患者,并分别分层为训练集和验证集。通过受试者操作特征曲线(AUC)下面积评估预测准确性。使用Cox回归分析确定对总生存期(OS)和无瘤生存期(TFS)有显著影响的因素。采用Kaplan-Meier法和Log秩检验进行生存分析。
GAR的AUC为0.70(P<0.001)。GAR的最佳截断值为0.91,其敏感性为78.1%,特异性为60.4%(P<0.001),据此将HCC患者分为高危(>0.91)和低危(≤0.91)组。时间依赖性ROC显示,GAR对1年、3年和5年OS预测的AUC分别为0.60、0.69和0.62。此外,通过单因素和多因素Cox回归分析,GAR在训练队列和验证队列中均被确定为OS和TFS的独立危险因素,也是巴塞罗那临床肝癌C期或无血管侵犯患者的良好预后指标。值得注意的是,GAR对生存的AUC优于几个潜在的预后指标(P<0.05)。
我们在两个接受根治性肝切除术的HCC患者独立队列中确定GAR为预后指标。GAR评分降低的患者与更好的OS和TFS显著相关。